Clinical Trial Search

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Emotion Recognition as Measured by the Emotion Recognition-40 at the 6 Week Time Point — 7.25; 6.67; 4.38; 6.17 number of correct responses — p=.61

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…

Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale

Primary: Error Percentage in Antisaccade Task — 22.6; 29.1 Error Percentage in Antisaccade Task — p=<0.05

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 77.18; 58.46; 63.33; -26.29 unit on a scale

Primary: Number of Participants With Treatment Response Based on Total PANSS Scale Score — 195 Participants

Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072

Primary: Subjective Well-being Under Neuroleptic (SWN-20) Scale Total Score at Week 24 — 77.89 Units on a scale

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 85.19; 65.45; -26.60; -20.52 units on a scale

Primary: Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8 — 5.85; 7.28; 28.4; 12.1 ng/ml

Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase — 81.0; 81.5; 81.7; 79.7 score on a scale

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001

Primary: Time to First Treatment Failure — 416; 226 Days

Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials

Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90

Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)

Primary: Cognitive Function- Digit Span Total — 13.3; 14.1 Items correct

Primary: Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale at Week 10 — 3.55; 0.82 Units on a scale — p=0.000

Primary: Number of Participants With Adverse Event and Adverse Drug Reaction — 9; 9; 11; 5 Participants